Aller au contenu principal
ProhibitedBinding ruleGBOriginal is EnglishImport de la source officielle contrôlé

Gallium arsenide

The consolidated GB Cosmetics Regulation lists this record in Annex II.

Décision réglementaire et conditions complètes

Statut
Prohibited
Rôle juridique
Binding rule
Résumé réglementaire
The consolidated GB Cosmetics Regulation lists this record in Annex II.
Conditions et restrictions
A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. Ouvrez la source citée et appliquez les exigences applicables à l’ensemble du marché ci-dessous.

Identité de la substance

Nom dans la source officielle
Gallium arsenide
CAS
1303-00-0
EC
215-114-8
Correspondance d’identité
standalone:official_gb_annex

Aperçu multi-marchés pour cette identité

Fiches exactes associées actuellement présentes sur ce site. L’absence d’un marché signifie qu’aucune correspondance exacte n’a été importée, et non une autorisation d’utiliser la substance.

6 jeux de données de marchés
Structure chimique 2D PubChem pour le CAS 1303-00-0
CAS 1303-00-0PubChem CID 14770

Chimie vérifiée pour le CAS 1303-00-0

Gallium arsenide

Gallium Arsenide can cause cancer according to California Labor Code. — California Office of Environmental Health Hazard Assessment (OEHHA)

Nom IUPAC
gallanylidynearsane
Formule moléculaire
AsGa
Masse moléculaire
144.645 g/mol
Masse exacte
143.84717 Da
Masse monoisotopique
143.84717 Da
Surface polaire topologique
0,0 Ų
Complexité moléculaire
10,0
Charge formelle
0
Donneurs de liaisons hydrogène
0
Accepteurs de liaisons hydrogène
0
Liaisons rotatives
0
Atomes lourds
2
Unités covalentes
1

Noms et synonymes signalés à PubChem

Gallium arsenide (GaAs)Gallium monoarsenideGallium monoarsenide (GaAs)GaAs27FC46GA44Gallium ArsenatumRefChem:58150215-114-8
15 autres noms signalés
CCRIS 4020HSDB 4376EINECS 215-114-8arsinogallaneUNII-27FC46GA44GalliummonoarsenideGallium Arsenide, piecesEC 215-114-8GALLIUM ARSENIDE [MI]Gallium arsenide, pieces, 99.999% trace metals basisGallium arsenide Optical Window, 12.7mm (0.5in) dia x 1mm (0.04in) thickGallium arsenide Optical Window, 12.7mm (0.5in) dia x 2mm (0.08in) thickGallium arsenide Optical Window, 25.4mm (1.0in) dia x 2mm (0.08in) thickGallium arsenide Optical Window, 50.8mm (2.0in) dia x 2mm (0.08in) thickGallium arsenide, (single crystal substrate), <100>, diam. x thickness 2 in. x 0.5 mm
Statistiques de structure avancées
Stéréocentres atomiques définis
0
Stéréocentres atomiques non définis
0
Stéréocentres de liaison définis
0
Stéréocentres de liaison non définis
0
Conformères 3D
0
Identifiants de structure lisibles par machine
SMILES
[Ga]#[As]
InChI
InChI=1S/As.Ga
InChIKey
JBRZTFJDHDCESZ-UHFFFAOYSA-N

Preuves issues de bases de données scientifiques complémentaires

NIH PubChem PUG-View
Correspondance exacte d’identifiant14770

Attributed physical-property, hazard, environmental and use annotations.

  • Substance: Gallium Arsenide Source: NTP Technical Reports
  • NTP Technical Report: TR-492: Toxicology and Carcinogenesis Studies of Gallium Arsenide (CASRN 1303-00-0) in F344/N Rats and B6C3F1 Mice (Inhalation Studies) (2000 ) Source: NTP Technical Reports
  • Peer Review Date: 05/21/99 Source: NTP Technical Reports
  • Conclusion for Male Rat: No Evidence Source: NTP Technical Reports
  • Conclusion for Female Rat: Clear Evidence Source: NTP Technical Reports
  • Conclusion for Male Mice: No Evidence Source: NTP Technical Reports
  • Conclusion for Female Mice: No Evidence Source: NTP Technical Reports
  • Summary: Under the conditions of these 2-year inhalation studies, there was no evidence of carcinogenic activity of gallium arsenide in male F344/N rats exposed to 0.01, 0.1, or 1.0 mg/m3. There was clear evidence of carcinogenic activity in female F344/N rats based on increased incidences of benign and malignant neoplasms in the lung. Increased incidences of benign neoplasms of the adrenal medulla and increased incidences of mononuclear cell leukemia were also considered to be exposure related. There was no evidence of carcinogenic activity in male or female B6C3F1 mice exposed to 0.1, 0.5, or 1.0 mg/m3.; Exposure to gallium arsenide caused a spectrum of nonneoplastic lesions in the lung of rats and mice, the larynx of male rats and hyperplasia of the tracheobronchial lymph node in mice. Source: NTP Technical Reports
  • Carcinogen Classification: 1, carcinogenic to humans. (L135) Source: Toxin and Toxin Target Database (T3DB)
  • First Aid: EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.; SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.; INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. IMMEDIATELY call a physician and be prepared to transport the victim to a hospital even if no symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Ap Source: CAMEO Chemicals
  • Signal: Danger Source: Regulation (EC) No 1272/2008 of the European Parliament and of the Council
  • GHS Hazard Statements: H350: May cause cancer [Danger Carcinogenicity]; H360F: May damage fertility [Danger Reproductive toxicity]; H372: Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] Source: Regulation (EC) No 1272/2008 of the European Parliament and of the Council
  • Precautionary Statement Codes: P203, P260, P264, P270, P280, P318, P319, P405, and P501 (click each P-code to see the statement) Source: Regulation (EC) No 1272/2008 of the European Parliament and of the Council
  • Note: This chemical does not meet GHS hazard criteria for 6.2% (7 of 112) of reports. Source: European Chemicals Agency (ECHA)
  • Signal: Danger Source: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H350 (88.4%): May cause cancer [Danger Carcinogenicity]; H360 (50.9%): May damage fertility or the unborn child [Danger Reproductive toxicity]; H372 (88.4%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] Source: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P203, P260, P264, P270, P280, P318, P319, P405, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 112 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 7 of 112 reports by companies.; There are 6 notifications provided by 105 of 112 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
  • Signal: Danger Source: NITE-CMC
  • GHS Hazard Statements: H350: May cause cancer [Danger Carcinogenicity]; H360: May damage fertility or the unborn child [Danger Reproductive toxicity]; H370: Causes damage to organs [Danger Specific target organ toxicity, single exposure]; H372: Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] Source: NITE-CMC
  • Precautionary Statement Codes: P203, P260, P264, P270, P280, P308+P316, P318, P319, P321, P405, and P501 (click each P-code to see the statement) Source: NITE-CMC
  • Signal: Danger Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
  • Health Effects: Arsenic poisoning can lead to death from multi-system organ failure, probably from necrotic cell death, not apoptosis. Arsenic is also a known carcinogen, esepcially in skin, liver, bladder and lung cancers. (T1, L20) Source: Toxin and Toxin Target Database (T3DB)
  • Toxicity Summary: Arsenic and its metabolites disrupt ATP production through several mechanisms. At the level of the citric acid cycle, arsenic inhibits pyruvate dehydrogenase and by competing with phosphate it uncouples oxidative phosphorylation, thus inhibiting energy-linked reduction of NAD+, mitochondrial respiration, and ATP synthesis. Hydrogen peroxide production is also increased, which might form reactive oxygen species and oxidative stress. Arsenic's carginogenicity is influenced by the arsenical binding of tubulin, which results in aneuploidy, polyploidy and mitotic arrests. The binding of other arsenic protein targets may also cause altered DNA repair enzyme activity, altered DNA methylation patterns and cell proliferation. (T1, A17) Source: Toxin and Toxin Target Database (T3DB)

Mis en correspondance par: Existing checksum-valid CAS to unique PubChem CID match. Récupéré le: 2026-08-31. Ouvrir la fiche source

Les classifications scientifiques et les annotations de danger apportent du contexte et ne remplacent pas la décision réglementaire propre au marché indiquée ci-dessus.

Couverture des sources complémentaires et état des correspondances
SourceRésultatVérifié
NIH PubChem PUG-ViewCorrespondance exacte2026-08-31

Une absence de correspondance enregistrée est une preuve utile que la source a été vérifiée ; ce n’est pas l’affirmation que la substance n’existe pas ailleurs.

Récupéré depuis NIH PubChem le 2026-09-02 par correspondance CAS à somme de contrôle valide. Les propriétés chimiques ne remplacent pas la décision réglementaire de cette page.

Source officielle et provenance

Source enregistrée
Great Britain Cosmetics Regulation — consolidated Annexes II–VI and amendments
Référence de la source
GB Cosmetics Regulation, Annex II, entry 1564
Identifiant de la fiche source
II-1564
Version de la source
2026-08-15
Langue de la source
English
État de la traduction
Original is English
Date d’effet
2026-08-15
Source mise à jour le
2026-08-19
Instantané vérifié le
2026-08-30 04:51 UTC
Méthode de validation
legislation.gov.uk XML table parse; {'II': 1758, 'III': 326, 'IV': 154, 'V': 57, 'VI': 34}
SHA-256
e3a386d950f54c6e7a7f9e784d1bd46e52de725137e89d5630709824475215d8

Notes du jeu de données enregistré

Couverture du jeu de données
Complete consolidated GB Annexes II–VI, with later amendments versioned separately
Note sur l’autorité
Binding GB schedules and versioned amendments to retained Regulation 1223/2009; applies to England, Wales and Scotland, not Northern Ireland
Licence de la source
Open Government Licence v3.0 / Crown copyright
Attribution
Contains public sector information licensed under the Open Government Licence v3.0.

Place de cette fiche dans le jeu de données du marché

2329
fiches Great Britain actuelles
1758
fiches marquées Prohibited
2329
fiches de cette version de la source
2015
fiches du marché avec identité CAS

Répartition des statuts

Un texte de conditions est présent pour 517 des 2329 fiches actuelles. Un champ de conditions vide est interprété selon le type de fiche ci-dessus ; il n’est jamais converti en une affirmation d’utilisation sans restriction.

Great Britain contexte du marché

Complete consolidated annex dataset

Version de la couverture : GB retained Regulation 1223/2009 schedules, effective 15 August 2026

Current consolidated Annexes II–VI for England, Scotland and Wales.

Liste de contrôle de vérification

  1. Confirm INCI/CAS/EC identity.
  2. Review every current GB Annex II–VI match.
  3. Check commencement dates and later statutory instruments.
  4. Verify SCPN, responsible-person, safety-report and labelling duties.

Sources officielles du marché

Procédure de vérification et exhaustivité de la fiche

Avant d’utiliser ce résultat dans une décision de conformité

  1. Confirmez que « Gallium arsenide » et chaque identifiant CAS/CE correspondent à la matière de votre spécification fournisseur.
  2. Confirm INCI/CAS/EC identity.
  3. Review every current GB Annex II–VI match.
  4. Check commencement dates and later statutory instruments.
  5. Verify SCPN, responsible-person, safety-report and labelling duties.
  6. Consignez la version de la source et revérifiez auprès de l’autorité de réglementation avant la fabrication, la notification ou la mise sur le marché.

Champs disponibles dans cette fiche

  • Nom officiel de la substanceDisponible
  • CASDisponible
  • ECDisponible
  • Texte de condition distinctAbsent de la ligne source
  • Date d’effetDisponible
  • Empreinte de l’instantané et méthodeDisponible

Questions auxquelles cette page répond

This official record identifies the substance as prohibited for cosmetic use in the stated market scope. Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework.

La fiche cite GB Cosmetics Regulation, Annex II, entry 1564, version de la source 2026-08-15. Ouvrir la source officielle.

Non. Le CAS aide à déterminer l’identité, mais les juridictions peuvent classer différemment une même substance et appliquer des champs d’application, limites, avertissements et dates de transition différents.

Citation stable

Gallium arsenide. GB Cosmetics Regulation, Annex II, entry 1564. Great Britain. Source version 2026-08-15. CosIng Checker regulatory record: https://cosingchecker.com/fr/regulations/gb/records/5919/

Citez l’autorité de réglementation comme autorité juridique. Cette page est un index structuré de preuves et une aide à la vérification, et non un substitut au texte officiel ni à une évaluation juridique professionnelle.

Interprétation et limites pour Great Britain

This official record identifies the substance as prohibited for cosmetic use in the stated market scope.

Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

Comment interpréter le rôle juridique

The cited row forms part of a binding rule or legally incorporated list for this market.

Preuves sur cette page

  • Résultat enregistré : Prohibited
  • Rôle juridique : Binding rule
  • Version de la source : 2026-08-15
  • Date d’effet : 2026-08-15

Ce que cela ne prouve pas

No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework.

Recherche complémentaire sur la substance auprès de sources faisant autorité

Aucune de ces sources ne prévaut sur la décision de marché ci-dessus.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

Rechercher cette identité à la source

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

Rechercher cette identité à la source

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

Rechercher cette identité à la source

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

Rechercher cette identité à la source

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

Rechercher cette identité à la source

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

Rechercher cette identité à la source

US EPA CompTox CTX APIs

Clé d’API requise pour l’import

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

Rechercher cette identité à la source